Articles on survival

MEHMET ZAHİD KOÇAK, MURAT ARAZ, melek karakurt eryılmaz, Mustafa Korkmaz, MEHMET ARTAÇ

Mevlana Tıp Bilimleri, 2024, Vol 4, Issue 1, Page 18-22

Aim: Bevacizumab is a target therapy drug inhibiting vascular endothelial growth factor (VEGF). High serum VEGF levels are related to increased visceral and abdominal fat mass. We aim to observe the relation of body mass index (BMI) with survival in metastatic colorectal cancer (mCRC) receiving...